Two Onc Docs Uromigos x Metastatic Bladder Cancer 2023 UPDATES
10 snips
Dec 18, 2023 
Dr. Tom Powles and Dr. Brian Rini discuss 2023 updates for metastatic bladder cancer, including staging, treatment options, and variant histologies. They highlight the efficacy and adverse event profile of single agent pembrolizomab and mabidotin. The podcast also covers new drugs in oncology and treatment options for urethral carcinoma. Additionally, they discuss less common histologic types of bladder cancer and the challenges of variant histologies for personalized treatment approaches.
AI Snips
Chapters
Transcript
Episode notes
Order NGS Early, Start Treatment Fast
- Do send NGS early for metastatic urothelial carcinoma but start treatment promptly and not wait for results.
- Obtain results during chemotherapy maintenance so actionable alterations are available later.
Speed Matters In Visceral Disease
- Starting timely systemic therapy is critical because patients with visceral disease can deteriorate quickly.
- Single-agent checkpoint inhibitors risk delayed control for many patients who may never reach second-line therapy.
EV-302 Is Practice-Changing
- EV-302 (enfortumab vedotin + pembrolizumab) produced striking OS and PFS improvements versus chemo and may become new frontline standard.
- The trial showed high response and CR rates leading to durable remissions in many patients.